{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:38:10Z","timestamp":1789616290263,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jconrel.2024.01.002","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T22:40:25Z","timestamp":1704926425000},"page":"479-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants"],"prefix":"10.1016","volume":"366","author":[{"given":"Lei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanfan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muye","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaiyao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Entao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.01.002_bb0005","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1056\/NEJMc2119236","article-title":"SARS-CoV-2 omicron variant neutralization in serum from vaccinated and convalescent persons","volume":"386","author":"R\u00f6ssler","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0010","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0015","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41467-021-21037-2","article-title":"A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0020","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/d41573-022-00035-z","article-title":"The mRNA vaccine development landscape for infectious diseases","volume":"21","author":"Kumar","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0040","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0050","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0055","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9450","article-title":"CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0060","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0065","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1038\/s41467-020-19156-3","article-title":"Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0070","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/diagnostics12071555","article-title":"Current evidence in SARS-CoV-2 mRNA vaccines and post-vaccination adverse reports: knowns and unknowns","volume":"12","author":"Mouliou","year":"2022","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.jconrel.2024.01.002_bb0075","doi-asserted-by":"crossref","first-page":"054","DOI":"10.30574\/gscarr.2023.14.2.0047","article-title":"Comparison of COVID-19 vaccine\u2019s side effects between mRNA and inactivated virus vaccine for health workers","volume":"14","author":"Munir","year":"2023","journal-title":"GSC Adv. Res. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2024.01.002_bb0080","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3390\/vaccines11071160","article-title":"Evaluation of antibody response and adverse effects following heterologous COVID-19 vaccine booster with mRNA vaccine among healthcare workers in Indonesia","volume":"11","author":"Soegiarto","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0085","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0090","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0100","first-page":"e193","article-title":"Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial, the lancet","volume":"3","author":"Chen","year":"2022","journal-title":"Microbe"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0105","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2024.01.002_bb0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/nat.2018.0734","article-title":"MicroRNAs enable mRNA therapeutics to selectively program cancer cells to self-destruct","volume":"28","author":"Jain","year":"2018","journal-title":"Nucleic Acid Ther."},{"issue":"26","key":"10.1016\/j.jconrel.2024.01.002_bb0115","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"issue":"12","key":"10.1016\/j.jconrel.2024.01.002_bb0120","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0125","series-title":"Improving mRNA Vaccine Safety and Efficiency with Cationized Lipid Nanoparticle Formula","author":"Peng","year":"2023"},{"issue":"6","key":"10.1016\/j.jconrel.2024.01.002_bb0130","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11095-022-03166-5","article-title":"Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size","volume":"39","author":"Di","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0140","series-title":"Comirnaty EPAR Public Assessment Report","author":"EMA","year":"2020"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0145","series-title":"Spikevax (Previously COVID-19 Vaccine Moderna) EPAR Assessment Report","author":"EMA","year":"2021"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10492","article-title":"Nanomaterials for mRNA-based therapeutics: challenges and opportunities","volume":"8","author":"Li","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-021-00634-z","article-title":"A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.02.019","article-title":"Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination","volume":"125","author":"Persano","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0165","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.apsb.2022.11.013","article-title":"An mRNA vaccine elicits STING-dependent antitumor immune responses","volume":"13","author":"Chen","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0170","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0175","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/JS9.0000000000000246","article-title":"The SARS-CoV-2 omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties \u2013 an alarming global threat of a surge in COVID-19 cases again?","volume":"109","author":"Chakraborty","year":"2023","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0185","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0200","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.chom.2020.11.012","article-title":"D614G spike mutation increases SARS CoV-2 susceptibility to neutralization","volume":"29","author":"Weissman","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0210","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-023-06025-4","article-title":"SARS-CoV-2 omicron boosting induces de novo B cell response in humans","author":"Alsoussi","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0215","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0220","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMcibr2106054","article-title":"Spike D614G \u2014 a candidate vaccine antigen against Covid-19","volume":"384","author":"Koenig","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0225","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.abb9983","article-title":"Site-specific glycan analysis of thSARS-CoV-2 spike","volume":"369","author":"Watanabe","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0230","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1074\/jbc.C300520200","article-title":"A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2","volume":"279","author":"Wong","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0235","article-title":"Characterization of two heterogeneous lethal mouse-adapted SARS-CoV-2 variants recapitulating representative aspects of human COVID-19","volume":"13","author":"Yan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0240","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0245","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0250","doi-asserted-by":"crossref","first-page":"2202590","DOI":"10.1002\/adhm.202202590","article-title":"Novel ionizable lipid nanoparticles for SARS-CoV-2 omicron mRNA delivery","author":"Long","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0255","doi-asserted-by":"crossref","first-page":"2209624","DOI":"10.1002\/adma.202209624","article-title":"Unsaturated, trialkyl ionizable lipids are versatile lipid-nanoparticle components for therapeutic and vaccine applications","volume":"35","author":"Lam","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0260","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0265","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1016\/j.ymthe.2022.07.007","article-title":"mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells","volume":"30","author":"Bevers","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0270","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba6466","article-title":"A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain","volume":"5","author":"Swanson","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0275","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0280","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0285","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0290","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0295","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","article-title":"A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice","volume":"53","author":"Laczk\u00f3","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2024.01.002_bb0300","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41467-023-36110-1","article-title":"Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models","volume":"14","author":"Corleis","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0305","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010255","article-title":"Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses","volume":"18","author":"Ndeupen","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2024.01.002_bb0315","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T16:33:02Z","timestamp":1738081982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":63,"alternative-id":["S0168365924000063"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.002","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}